Ebola outbreak alert prompts Co-Diagnostics to announce Bundibugyo virus assay strategy

 

Ebola outbreak alert prompts Co-Diagnostics to announce Bundibugyo virus assay strategy.

• Co-Diagnostics released a May 19, 2026 press release detailing completed assay development strategy for Bundibugyo virus (BDBV), an Ebola strain.
• Announcement follows WHO PHEIC declaration (May 17) and CDC guidance on outbreaks in DRC (8 confirmed cases, many suspected) and Uganda.
• Strategy uses the company’s patented Co-Dx PCR platform for rapid, decentralized testing and cloud-connected real-time situational awareness.
• CEO highlighted preparedness for emerging threats and openness to collaboration with government/NGO partners on test development.
• Stock rose ~46% in premarket on May 19 (from $1.37 close on May 18 to ~$2.01), matching the reported 45.98% move.
• Platform (including PCR Home®/Pro® concepts) remains under FDA and other regulatory review and is not yet available for sale.
• Builds on recent strategic moves like Saudi facility lease and South Asia expansion but is directly tied to the fresh global health alert.

https://finviz.com/quote?t=CODX&p=d